Is Moderna Stock a Buy?
's (NASDAQ: MRNA) wild success in the COVID-19 vaccine market has worn off. The company's revenue, earnings, and stock price have been moving in the wrong direction for the past three years, a period during which the biotech has lost 85% of its value.
Despite what it seems, though, Moderna has made clinical and regulatory progress. If that continues and the company's plans pan out, it could deliver excellent returns to investors who initiate positions now. Let's find out whether this scenario is realistic for Moderna.
Though we are no longer in a state of extreme emergency, COVID-19 is still a problem. Thousands of people continue to get sick, become hospitalized, and die. That's especially the case with those who are at a higher risk from the disease, including seniors and people with some pre-existing conditions. So, there remains a market for Moderna's COVID-19 vaccine, although the demand has fallen off a cliff since 2021. In the third quarter, Moderna reported $1.9 billion in revenue, roughly flat compared to the year-ago period.
Source Fool.com
Moderna Inc. Aktie
Bei der Moderna Inc. Aktie halten sich Buy- und Sell-Einschätzungen im Gleichgewicht.
Das Community-Kursziel von 22 € für Moderna Inc. deutet auf eine deutliche Minderung um mehr als 20% gegenüber dem aktuellen Kurs von 34.01 € hin.
